Tropisetron in the prevention of chemotherapy-induced acute emesis in pediatric patients

Turkish Journal of Pediatrics

Volumn 41, Issue 2, 1999, Pages 207-218

  Uysal, Kamer Mutafoǧlu ^a   Olgun, Nur ^a   Sarialioǧlu, Faik ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Acute emesis; Adolescent; Antiemetic; Children; Tropisetron

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PREDNISONE; PROCARBAZINE; TIOGUANINE; TROPISETRON; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; VOMITING; XEROSTOMIA;

ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DIPHENHYDRAMINE; HUMANS; INDOLES; NAUSEA; VOMITING;

EID: 0032935851     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Allen JC, Gralla R, Reilly L, et al. Metoclopramide: dose related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 1985; 3: 1136-1141.
2. Terrin BN, McWilliams NB, Maurer HM. Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy. J Pediatr 1984; 104: 138-140.
3. th International Congress of Chemotherapy. Istanbul, Turkey July 19-24, 1987: 266-268.
4. Pinkerton CR, Williams D, Woote C, et al. 5 HT3 antagonist ondansetron: an effective outpatient antiemetic in cancer treatment. Arch Dis Child 1990; 65: 822-825.
5. Lemerle J, Amaral D, Southal DP, et al. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients. Eur J Cancer 1991; 27, 1081-1083.
6. Benoit Y, Hulstaert F, Vermylen C, et al. Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy. Med Pediatr Oncol 1995; 25: 457-462.
7. Cefalo G, Rottoli L, Armiraglio A, et al. Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments. Am J Pediatr Hematol Oncol 1994; 16: 242-245.
8. Hachimi-Idrisis S, De Schepper J, Maurus R. Prevention of emesis by ICS 205-930 in children receiving cytotoxic chemotherapy. Eur J Cancer 1993; 29: 854-856.
9. Berberoǧlu S. Prevention of emesis by tropisetron in children receiving combined chemotherapy with cisplatin. Pediatr Hematol Oncol 1995; 12: 479-483.
10. Bleiberg H, Van Belle S, Paridaens R. Compassionate use of tropisetron in patients at high risk of severe emesis. Ann Oncol 1993; 4 (Suppl): 43-45.
11. Sorbe B, Hogberg T, Himmelmann A, et al. Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. Eur J Cancer 1994; 30A: 629.
12. Van Belle SJP, Cocquyt VF, Bleiber H, et al. Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. Anti-Cancer Durgs 1995; 6 (Suppl): 22-30.
13. Gershanovich M, Kolygin B, Pirgoch N. Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Ann Oncol 1993; 4: (Suppl): 35-37.
14. Dolginn MJ, Katz ER, Doctors SG, et al. Caregivers' perception of medical compliance in adolescents with cancer. J Adolesc Health Care 1986; 7:22-27.
15. Rolia F, Ballatori E, Tonato M, et al. 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer 1997; 33: 1364-1370.
16. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6: 805-810.
17. Jantunen IT, Muhonen TT, Kataja VV, et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy-a randomised study. Eur J Cancer 1993; 29A: 1669-1672.
18. Marty M, Kleisbauer JP, Fournel P, et al. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 1995; 6: 15-21.
19. Navari R, Hesketh P, Hall S, et al. On behalf of the Granisetron Study Group. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242-1248.
20. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assesment of efficacy, safety and patient preference. Eur J Cancer 1994; 30A: 1083-1088.